Christopher Cannon, a cardiologist at Brigham and Women's Ho

UNITED STATES - APRIL 12: Christopher Cannon, a cardiologist at Brigham and Women's Hospital, speaks about Merck & Co.'s experimental arthritis drug Arcoxia, during a break in a Food and Drug Administration public hearing on the drug's approval, April 12, 2007, in Gaithersburg, Maryland. Cannon worked as a consultant to Merck on Arcoxia. Arcoxia would be a ``a potential public health disaster'' if approved, said a U.S. regulator long critical of Vioxx, a predecessor that was withdrawn because of dangerous side effect. (Photo by Stephanie Kuykendal/Bloomberg via Getty Images)